Pregnant and breastfeeding women should avoid these therapies unless recommended by their physician
Therefore, patients must maintain open communication with their healthcare team about all medications they take, including over-the-counter drugs and herbal products
These results follow similar findings from the companys ATTAIN-1 trial released earlier this month, which tested the drug on people who were overweight or obese without type 2 diabetes (in general, people without diabetes tend to lose more weight from GLP-1 therapy than those with diabetes)
Mahfouz R, El-Rewini H, Ghoneim SI, Sheta A, Ali EA, Ibrahim M
The Bottom Line Although AOD-9604, MOTS-c, Tesamorelin, Semaglutide, and Tirzepatide are often discussed together, they serve very different purposes